Bellevue Group Ag Amicus Therapeutics, Inc. Transaction History
Bellevue Group Ag
- $5.93 Billion
- Q3 2024
Shares
2 transactions
Others Institutions Holding FOLD
# of Institutions
313Shares Held
314MCall Options Held
516KPut Options Held
833K-
Vanguard Group Inc Valley Forge, PA28.8MShares$287 Million0.01% of portfolio
-
Perceptive Advisors LLC New York, NY28.1MShares$280 Million7.83% of portfolio
-
Black Rock Inc. New York, NY24.4MShares$243 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA24MShares$239 Million0.05% of portfolio
-
Avoro Capital Advisors LLC New York, NY23.2MShares$231 Million3.72% of portfolio
About AMICUS THERAPEUTICS, INC.
- Ticker FOLD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 280,497,984
- Market Cap $2.8B
- Description
- Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant bas...